Current Pharmacogenomics and Personalized Medicine (CPPM) is an international peer reviewed biomedical journal that publishes expert reviews, and state of the art analyses on all aspects of pharmacogenomics and personalized medicine under a single cover. This journal follows the International Committee of Medical Journal Editors (http://www.icmje.org) guidance for authorship, peer review, and editorial independence.

The CPPM addresses the complex transdisciplinary challenges and promises emerging from the fusion of knowledge domains in therapeutics and diagnostics (i.e., theragnostics). The journal bears in mind the increasingly globalized nature of health research and services, and the diverse technologies, stakeholders and interdisciplinary expertise that collectively drive this rapidly evolving and hybrid knowledge frontier in biomedicine. The journal became an integrated new title addressing both pharmacogenomics and personalized medicine effective 2008.

The journal strives to move beyond the traditional compartmentalization of biomarker technology platforms, and their application contexts through a multidisciplinary integrated perspective on personalization of health interventions (e.g., drug therapy, nutrition) and more generally, variability in host-environment interactions and its mechanistic determinants. The journal is published four times per year and printed on acid-free paper.

The journal gives priority to insightful, lucid, authoritative reviews and in-depth feature commentaries that present an original and balanced synthesis of the literature on personalized medicine and enabling omics technologies including, but not limited to, genomics, transcriptomics, proteomics and metabolomics. Research articles will be considered for peer reviewed publication provided that they report an original finding pertinent for personalized medicine.

All application contexts from preclinical and translational research to routine clinical medicine are eligible for peer review, including drug target discovery, biomarker guided clinical drug development, bioinformatics, bioethics, health technology assessment, novel diagnostics to forecast disease susceptibility, pharmacoeconomics, risk assessment models, prospective innovation analysis, science and society interactions, as long as the authors contextualize and integrate these subjects specifically for personalized medicine. Priority will be given to expert reviews that include original ideas or new ways of treating concepts related to personalized medicine (e.g., pharmacogenomics, nutrigenomics, pharmacoproteomics, systems biology). We aim to integrate molecular and translational science with social, ethical and policy dimensions in personalized medicine.

All manuscripts submitted for publication will be immediately subjected to editorial scrutiny. Manuscripts that do not conform to the CPPM format and editorial style will be returned to the authors. Only those articles that may potentially pass the rigorous standards of the peer review process are sent out for critical appraisal by independent expert referees invited from the international editorial board and the broader scientific community.

The CPPM offers a unique multidisciplinary international forum and has become an indispensable reading for academic researchers, clinicians and health professionals, policy makers as well as pharmaceutical/biotechnology industry, healthcare management and government stakeholders who share an interest in pharmacogenomics and personalized medicine.